Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Michl

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
Gut|January 31, 2012
Targeting cathepsins: a new glimmer of hope for pancreatic cancer therapy?Patrick Michl
Cell Cycle (Georgetown, Tex.)|December 17, 2005
CUTL1: a key mediator of TGFbeta-induced tumor invasionPatrick Michl, Julian Downward
Gut|October 9, 2023
Female advantage in neoadjuvant pancreatic cancer therapy: is it down to macrophages?Patrick Michl, Laura Roth
Oncoimmunology|July 23, 2014
The role of CUX1 in antagonizing NF-κB signaling in TAMsBenjamin Kühnemuth, Patrick Michl
Gut|December 9, 2017
Overcoming immune evasion in pancreatic cancer: the combination mattersPatrick Michl, Sebastian Krug
Journal of Crohn'S & Colitis|December 9, 2017
Sexual Dysfunction in Patients With Inflammatory Bowel Disease is not just a Matter of Quality of LifeJens Walldorf, Patrick Michl
The Lancet. Oncology|March 6, 2017
Targeted therapy of pancreatic cancer: biomarkers are neededJörg Kleeff, Patrick Michl
Digestion|April 7, 2017
Esophageal Cancer: New Insights into a Heterogenous DiseaseSebastian Krug, Patrick Michl
Gut|October 20, 2023
Targeting myeloid signalling pathways to unleash T cellsPatrick Michl, Sebastian Krug
Zeitschrift Fur Gastroenterologie|December 8, 2020
[Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer Cell 2020; 181: 424-441]Sebastian Krug, Patrick Michl
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Gut|January 31, 2012
Targeting cathepsins: a new glimmer of hope for pancreatic cancer therapy?Patrick Michl
Cell Cycle (Georgetown, Tex.)|December 17, 2005
CUTL1: a key mediator of TGFbeta-induced tumor invasionPatrick Michl, Julian Downward
Gut|October 9, 2023
Female advantage in neoadjuvant pancreatic cancer therapy: is it down to macrophages?Patrick Michl, Laura Roth
Oncoimmunology|July 23, 2014
The role of CUX1 in antagonizing NF-κB signaling in TAMsBenjamin Kühnemuth, Patrick Michl
Gut|December 9, 2017
Overcoming immune evasion in pancreatic cancer: the combination mattersPatrick Michl, Sebastian Krug
Journal of Crohn'S & Colitis|December 9, 2017
Sexual Dysfunction in Patients With Inflammatory Bowel Disease is not just a Matter of Quality of LifeJens Walldorf, Patrick Michl
The Lancet. Oncology|March 6, 2017
Targeted therapy of pancreatic cancer: biomarkers are neededJörg Kleeff, Patrick Michl
Digestion|April 7, 2017
Esophageal Cancer: New Insights into a Heterogenous DiseaseSebastian Krug, Patrick Michl
Gut|October 20, 2023
Targeting myeloid signalling pathways to unleash T cellsPatrick Michl, Sebastian Krug
Zeitschrift Fur Gastroenterologie|December 8, 2020
[Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer Cell 2020; 181: 424-441]Sebastian Krug, Patrick Michl
Pageof 16